HidraMed Solutions Accelerates Market Commercialisation with key milestones achieved
In the second half of 2023, HidraMed Solutions realised several pivotal milestones crucial to its global mission of delivering transformative wound care solutions for chronic patients. Highlights include the enhancement of the board of directors and clinical advisory board with world renowned experts, receipt of European patent approval for their adhesive-free wound care system, global industry recognition of their innovative technology and substantial strides in product accessibility through reimbursement systems in key US and UK markets.
Phil Cooper Appointed as New HidraMed Solutions Chair
HidraMed Solutions, the innovator behind HidraWear Adhesive-Free Wound Care Technology, has named Phil Cooper, a seasoned wound management leader, the new Chair of the Board of Directors. Formerly the Executive President of the Wound Care Division at Molnlycke Healthcare, Mr. Cooper brings a wealth of experience and a successful track record in transforming companies into global market leaders. In his new role, he aims to guide HidraMed Solutions towards addressing an untapped market segment potentially worth over $2 billion in the US and EU alone.
Dr. Lev-Tov Joins Clinical Advisory Board
HidraMed Solutions proudly welcomes Dr. Lev-Tov to its Clinical Advisory Board. Recognised globally for his expertise in HS treatment, wound healing, and medical dermatology, Dr. Lev-Tov’s insights are crucial to HidraMed’s mission of revolutionising HS care.
Having advised the company since its inception, formalising this relationship is a milestone for both business growth in the U.S. and advancing their goal of enhancing the daily lives of those affected by HS through advanced wound care solutions.
With Dr. Lev-Tov’s clinical expertise, HidraMed is poised to innovate and refine its solutions, ultimately making a meaningful difference in reducing daily pain and improving the quality of life for individuals living with HS.
These strategic appointments and technological advancements position HidraMed Solutions at the forefront of the wound care industry, poised for transformative growth and enhanced patient care in the year ahead.
Patent Granted for HidraWear Adhesive-Free Wound Care Technology
HidraMed Solutions celebrated a significant milestone with the European Patent Office granting a patent for its groundbreaking ‘HidraWear Adhesive-Free Wound Care Technology.’ The technology offers a revolutionary approach to chronic wound care, particularly beneficial for challenging-to-dress areas caused by conditions like Hidradenitis Suppurativa (HS).
The European patent not only strengthens HidraMed’s market position but also underscores its commitment to improving patient outcomes and reducing healthcare costs.
Hidrawear Wins Overall Innovation Award at the 2023 Advanced Wound Care Summit Boston
HidraWear was the overall winner of the coveted Innovation Award at the Advanced Wound Care Summit in Boston. This annual summit is woundcare’s only industry led-forum and gathering of businesses, key figures, and thought leaders from the global wound care sector.
Amongst 11 outstanding finalists, HidraMed had the opportunity to present its revolutionary HidraWear technology and strategic vision to an audience of industry leaders. “It was a real honour for our innovation to be recognised amidst such pioneering companies and ideas” says Suzanne Moloney, HidraMed CEO
Increased Reimbursement Availability for HidraWear in Priority US And UK Markets
USA – Already widely available through US Commerical Health Insurance (incl Medicare and Medicaid) new agreements with Prism Medical Supplies, Cardinal Health and The Healthcare Store means HidraWear is now available to order through the preferred route for a significant majority of wound care and dermatology clinics across the US.
UK – On Monday 4th December 2023, Hidrawear wearable wound care was launched on the NHS Supply Chain allowing UK clinicians to now treat wounds in difficult to dress areas such as the Axilla, groin or buttocks.
